BTIG Keeps Their Hold Rating on Globus Medical (GMED)
I'm LongbridgeAI, I can summarize articles.BTIG analyst Ryan Zimmerman maintained a Hold rating on Globus Medical (GMED) in a July 10 report, with shares closing at $78.11. While Stifel Nicolaus also issued a Hold, RBC Capital recently kept a Buy rating on the stock. The report highlights Zimmerman's track record as a 3-star analyst covering the healthcare sector.
In a report released on July 10, Ryan Zimmerman from BTIG maintained a Hold rating on Globus Medical. The company’s shares closed yesterday at $78.11.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Zimmerman is a 3-star analyst with an average return of 2.8% and a 44.53% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Intuitive Surgical, and Medtronic.
In addition to BTIG, Globus Medical also received a Hold from Stifel Nicolaus’s Thomas Stephan in a report issued on July 8. However, yesterday, RBC Capital maintained a Buy rating on Globus Medical (NYSE: GMED).